By Sabela Ojea
Oncternal Therapeutics said it is reducing its workforce as it discontinues all product development while it goes through a strategic business review.
The clinical-stage oncology company on Thursday said that it will cut its workforce by 37%, equal to about 10 employees, to reduce its operating expenses. The move was unanimously approved by the board of directors a day earlier.
The company, which expects to book termination costs of about $1 million, said the decision comes after the results of ONCT-534 and ONCT-808 didn't show meaningful improvements or anti-tumor activity, respectively.
Oncternal Therapeutics is terminating these studies and will focus on exploring strategic alternatives including asset sales, licensing or other strategic transactions, and a merger, reverse merger or acquisition.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
September 12, 2024 18:14 ET (22:14 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.